Lateral Cervical Node Dissection in Differentiated Thyroid Cancer.

Sponsor
Centro de Excelencia en Enfermedades de Cabeza y Cuello (Other)
Overall Status
Recruiting
CT.gov ID
NCT06149637
Collaborator
Hospital Alma Mater de Antioquia (Other), Hospital San Vicente Fundación (Other), Clinica Las Vegas- Grupo QuironSalud (Other)
62
1
2
61
1

Study Details

Study Description

Brief Summary

The objective of this study is to compare shoulder and neck morbidity and the effectiveness of cervical lateral nodal dissection in patients with differentiated thyroid cancer and lateral metastases between the anterior and posterior approaches to the sternocleidomastoid muscle (SCM)

Condition or Disease Intervention/Treatment Phase
  • Procedure: Traditional neck dissection approach
  • Procedure: Anterior neck dissection approach
N/A

Detailed Description

The incidence of thyroid cancer has increased in recent decades, being responsible for 586,000 cases worldwide, ranking ninth in incidence in 2020. The rapid increase of thyroid cancer, particularly papillary thyroid cancer, has been largely attributed to the increasing use of ultrasound, along with increased use of other imaging modalities.

Similarly, analyzing the pattern of lymph node dissemination of well-differentiated thyroid carcinoma, Eskander et al., 2 reviewed all the pertinent literature up to 2011 (a total of 1,145 patients and 1,298 neck dissections) and reported an overall metastasis rate in patients taken to to surgery of 53.1%, 15.5%, 70.5%, 66.3%, 7.9% and 21.5% in levels IIa, IIb, III, IV, Va and Vb, respectively. For the Thus, the primary surgical treatment for lateral neck disease generally includes lateral neck dissection in conjunction with total thyroidectomy. Lymph node dissection should be performed in patients with biopsy-proven metastatic lateral cervical nodes. Jugular nodes located at levels II, III, and IV are the lateral neck compartments most commonly affected by CBDT and should be included in all therapeutic lateral neck dissections. Level V, which represents the posterior triangle of the neck, is affected less frequently. However, the Vb level must be dissected along with the other levels, and careful visualization and dissection of the spinal accessory nerve is paramount. Level V can be approached by an anterior approach by retracting the sternocleidomastoid muscle posteriorly, or by dissecting the posterior triangle behind the muscle sternocleidomastoid to the trapezius muscle. The precise extent of the neck dissection is a decision made based on the volume and location of the disease. The ATA recommends complete lymph node dissection (CLND), including levels II and V, for most patients with clinically evident lateral neck metastatic disease, although nuances regarding the extent of level V dissection are not clarified, in relation to whether level V should be included. Regarding the difference between the surgical techniques, the posterior approach to the sternocleidomastoid muscle involves a longer incision, where the dissection proceeds from the anterior edge of the trapezius muscle in a medial direction that includes the lymphatic contents of the supraclavicular fossa. The upper margin of this area presents the greatest risk of damage to the spinal accessory nerve. Furthermore, during the dissection of this region, several supraclavicular branches of the cervical plexus can be found. Some branches of the deep cervical plexus follow a course similar to that of the accessory nerve and may confuse the novice surgeon. In the case of the anterior approach, the incision is made up to the anterior edge of the ECM and once the accessory nerve has been identified at its insertion in the sternocleidomastoid, its course is traced superiorly to the posterior belly of the digastric. However, the effect of the anterior approach on the lymph node count and the risk of future recurrence at level V is uncertain. With these differences in terms of the approach in these two techniques, a greater length of skin incision, and greater dissection of the accessory nerve can be observed. and of the deep cervical plexus given the similar course to the XI nerve in the posterior approach, the question arises as to whether the surgical approach influences the patient's morbidity.

The main objective of the present study was to compare the morbidity and effectiveness measured in terms of lymph node count of emptying levels II to V by the anterior versus the posterior route in patients with well-differentiated thyroid cancer with lateral metastases.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
62 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized, parallel, multicenter stratified clinical trial with 1:1 allocation.Randomized, parallel, multicenter stratified clinical trial with 1:1 allocation.
Masking:
Single (Participant)
Masking Description:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Comparison of Two Routes of Surgical Approach to Lateral Cervical Node Dissection in Differentiated Thyroid Cancer Patients With Lateral Metastatic Disease: Randomized Clinical Trial
Actual Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Aug 31, 2024
Anticipated Study Completion Date :
Aug 31, 2028

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Traditional neck dissection approach

Traditional neck dissection approach

Procedure: Traditional neck dissection approach
.1. A transverse cervical incision is made with horizontal extension towards the affected side. 2. It is dissected through the subplatysmal plane, the posterior edge of the sternocleidomastoid muscle is dissected along its entire length. 3. Identification and dissection of the spinal nerve at Erb's point. 4. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it 5. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level 6. Identification and dissection of level III nodes 7. Identification and dissection of level IIA and IIB ganglia with identification and preservation of the accessory nerve.

Experimental: Anterior neck dissection approach

Anterior neck dissection

Procedure: Anterior neck dissection approach
A transverse cervical incision is made with horizontal extension towards the affected side. It is dissected through the subplatysmal plane, the anterior edge of the sternocleidomastoid muscle is dissected along its entire length. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level Identification and dissection of level III nodes Identification and dissection of level IIA and IIB nodes with identification and preservation of the accessory nerve.

Outcome Measures

Primary Outcome Measures

  1. Shoulder dysfunction [2 weeks, 3 months, 6 months, and 1 year]

    (SPADI shoulder pain and disability questionnaire, validated in Spanish) Minimun score 0, maximun 100, a higher score means higher disability

  2. Cervical disconfort [2 weeks, 3 months, 6 months, and 1 year]

    The Cervical Disability Index (IDC) validated in Spanish Minimun score 0, maximun 50, a higher score means higher disability

  3. Complications [30 days]

    Temporary or permanent accessory nerve injury measured in the physical examination by limitation of the lateral range of movement of the shoulder less than 50% Bleeding defined by the treating surgeon by physical examination Wound infection: infection in the first 30 days after surgery, diagnosed with at least one of the following criteria: presence of purulent discharge from the surgical wound, presence of microorganisms isolated by taking a culture of wound discharge , presence of at least one of the signs and symptoms of inflammation (pain, redness, edema, heat). Chylous fistula defined as milky discharge from the cervical drain with a triglyceride count higher than the serum. Mortality Re Operation before 30 days

Secondary Outcome Measures

  1. Total lymph node count. [30 days]

    Total number of resected and compromised lymph nodes according to the histopathology report

  2. Surgical time [30 days]

    Surgical time in minutes according to the surgical report

  3. Lateral lymph node recurrence [5 years]

    Number of participants with presence of tumor in the neck lymph nodes detected during follow-up by physical examination or imaging 6 months or more after primary surgery and confirmed cytopathologically.

  4. Dynamic response [5 years]

    Number of participants with excellent, incomplete biochemical, incomplete structural or undetermined response according to the ATA classification.

  5. Overall and disease-free survival [5 years]

    Overall and disease-free survival measured from the day of surgery until recurrence or termination of follow-up.

  6. Length of postoperative hospital stay. [30 days]

    Length of postoperative hospital stay.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients ≥ 18 years.

  2. Patients with macroscopic lymph node involvement identified by physical examination, imaging or intraoperatively in lateral neck.

  3. Patients with microscopic nodal involvement confirmed by FNAB (definition by the pathologist of suspected or confirmed metastatic papillary carcinoma according to the Bethesda criteria)

  4. Candidates for lateral lymph node dissection due to suspected or confirmed disease metastatic lymph nodes as defined by the treating surgeon.

  5. Patients requiring or not requiring thyroidectomy and/or central dissection concomitant with the dissection

Exclusion Criteria:
  1. Patients with a history of previous neck dissection

  2. Histological confirmation of medullary or anaplastic carcinoma

  3. Previous spinal nerve injury

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Alma Mater de Antioquia Medellin Antioquia Colombia 050010

Sponsors and Collaborators

  • Centro de Excelencia en Enfermedades de Cabeza y Cuello
  • Hospital Alma Mater de Antioquia
  • Hospital San Vicente Fundación
  • Clinica Las Vegas- Grupo QuironSalud

Investigators

  • Principal Investigator: Alvaro Sanabria, Universidad de Antioquia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alvaro Sanabria, Primary Researcher, Centro de Excelencia en Enfermedades de Cabeza y Cuello
ClinicalTrials.gov Identifier:
NCT06149637
Other Study ID Numbers:
  • IN53-2021
First Posted:
Nov 29, 2023
Last Update Posted:
Nov 29, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Alvaro Sanabria, Primary Researcher, Centro de Excelencia en Enfermedades de Cabeza y Cuello
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 29, 2023